Literature DB >> 21700734

Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas.

M J Rodrigues1, L Albiges-Sauvin2, J Wassermann3, P H Cottu4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21700734     DOI： 10.1093/annonc/mdr308

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  1 in total

1.  HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.

Authors:  Philippe Rouanet; Pascal Roger; Emilie Rousseau; Severine Thibault; Gilles Romieu; Andre Mathieu; Jacques Cretin; Gilbert Barneon; Mireille Granier; Aurelie Maran-Gonzalez; Jean P Daures; Florence Boissiere; Frederic Bibeau
Journal:  Cancer Med       Date:  2014-01-10       Impact factor: 4.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.